Form 4: Cyclo Therapeutics Director Receives Stock Grant in Lieu of Cash Compensation

William Conkling, a director at Cyclo Therapeutics, received 16,660 shares of common stock in lieu of cash compensation for the third quarter of 2024.

Summary

• William Conkling, a director of Cyclo Therapeutics, Inc., received 16,660 shares of common stock.
• These shares were granted in lieu of cash compensation as part of the company's non-employee director compensation policy.
• The grant represents compensation for the third quarter of 2024.
• The number of shares was calculated based on a price of $0.66 per share, which was the closing price on November 14, 2024.
• Following this transaction, Mr. Conkling beneficially owns 50,230 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to positively. The use of stock instead of cash is a positive sign for cash management.

Positives

• The grant of shares aligns director compensation with company performance.
• The use of stock instead of cash may preserve company cash reserves.

Industry Context

This type of stock grant is a common practice for compensating non-employee directors, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Many companies, especially in the biotech sector, use stock grants as part of their director compensation packages.
• This practice is generally considered standard for aligning director interests with shareholder value.
• The specific amount of stock granted is dependent on the company's compensation policy and the director's role.

Stakeholder Impact

• Shareholders may view the stock grant positively as it aligns director interests with company performance.
• The use of stock instead of cash may be seen as a positive for the company's financial health.

Key Dates

Keywords

Cyclo Therapeutics, Director Compensation, Stock Grant, Form 4, Insider Trading, Equity Compensation